BPC-157

Dr. Craig Koniver, who has used peptides with patients for more than a decade and now also trains other physicians in this work, considers BPC-157 the most versatile peptide we have worked with. For years it was the one we used most. Asked to sum it up, his answer is short: very anti-inflammatory._[14]

We used it with physically active patients protecting or repairing soft tissue, with people recovering from surgery or illness, for digestive complaints, and for inflammation that would not settle on its own._[14]

The tendon pattern explains why athletes found it first. Most training injuries do not happen in the muscle. Muscle strengthens quickly; the tendons and ligaments anchoring it adapt slowly, so problems concentrate at those attachment points - strains, tendinitis, sometimes a rupture. In our experience, BPC-157 was protective of exactly that tissue, and athletes at every level - weekend exercisers through professionals - used it with us for that reason. It is also how Dr. Koniver came to peptides in the first place: caring for competitive athletes who wanted to recover well without harsher compounds._[14]

Two more things we learned over the years. BPC-157 increases the number of growth hormone receptors on healing tissue, so we often paired it with peptides that prompt the body's own growth hormone release - one raises the signal, the other helps the tissue receive it. That matches Dr. Koniver's view of peptides in general: signals the body already understands, useful because they make the body's own signaling more efficient, not because they force anything. And on forms: injectable worked better than oral in our experience, with one exception - the gut lining, the tissue this molecule comes from, is where the oral form makes sense._[14]

On side effects: they were rare. Across years of use, BPC-157 was among the best-tolerated tools in our practice, and that record is the first reason Dr. Koniver trusts peptides as a category. He is also clear about what kind of evidence this is. Formal clinical trials are scarce for most peptides. His confidence comes from the physiological data and from long, careful observation of patients, not from trial results. Screening still came first: we ruled out active cancer and pregnancy before starting any patient on a peptide._[14]

Response was not instant. The pattern we saw with BPC-157 was improvement building over the first few weeks, then continuing: less inflammation, less pain, better function. We also used peptides episodically, the way Dr. Koniver teaches them: improve, then reassess, pause, or stop. They are not lifetime commitments._[14]

In recent years our clinical work moved from BPC-157 to pentadeca arginate (PDA), and the reason was regulatory, not clinical. In late 2023, BPC-157 was placed on the FDA's Category 2 compounding list, and the regulated pharmacies we source from could no longer prepare it. We did not lose confidence in BPC-157. We lost the supply channel we trust. PDA has the same fifteen-amino-acid backbone with one amino acid exchanged, and Dr. Koniver calls it "the new BPC". It has since earned its place on its own results. The clearest difference we have seen is speed: BPC-157 typically showed itself over a couple of weeks, while patients on PDA kept reporting change within days - foot, ankle, and knee complaints easing within the first few injections. These are clinical reports, not trial results, and the published research still belongs almost entirely to BPC-157. Dr. Koniver's position on PDA is plain: no reservations, very safe in his experience, very happy with it._[14]

That regulatory picture is now moving again, in a direction we are glad to see. BPC-157 came off the Category 2 list in April 2026, and in July 2026 the FDA's compounding advisory committee voted to recommend adding it to the approved compounding list. The final decision is still ahead; the regulatory status section below has the details. Our position is simple. BPC-157 is a peptide we know well and used with confidence for years, and we welcome every step that brings it back within reach of regulated, physician-supervised care._{[11, 15, 16]}‍